FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149357832> ?p ?o ?g. }

• W2149357832 endingPage "313" @default.
• W2149357832 startingPage "305" @default.
• W2149357832 abstract "Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme alpha-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. Both contain the same human enzyme, alpha-galactosidase A, but they are produced using different protein expression systems and have been approved for administration at different doses. To determine if there is recognizable biochemical basis for the different doses, we performed a comparison of the two drugs, focusing on factors that are likely to influence biological activity and availability. The two drugs have similar glycosylation, both in the type and location of the oligosaccharide structures present. Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation. The higher levels of phosphorylated oligomannose residues correlated with increased binding to mannose-6-phosphate receptors and uptake into Fabry fibroblasts in vitro. Biodistribution studies in a mouse model of Fabry disease showed similar organ uptake. Likewise, antigenicity studies using antisera from Fabry patients demonstrated that both drugs were indistinguishable in terms of antibody cross-reactivity. Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable. Therefore, the data from these studies provide no rationale for the use of these proteins at different therapeutic doses." @default.
• W2149357832 created "2016-06-24" @default.
• W2149357832 creator A5043847795 @default.
• W2149357832 date "2003-01-03" @default.
• W2149357832 modified "2023-10-05" @default.
• W2149357832 title "A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease" @default.
• W2149357832 cites W1490194415 @default.
• W2149357832 cites W1975351631 @default.
• W2149357832 cites W1975365119 @default.
• W2149357832 cites W1980392051 @default.
• W2149357832 cites W1995994862 @default.
• W2149357832 cites W1998619235 @default.
• W2149357832 cites W2000257500 @default.
• W2149357832 cites W2022356406 @default.
• W2149357832 cites W2026507072 @default.
• W2149357832 cites W2033081167 @default.
• W2149357832 cites W2033287927 @default.
• W2149357832 cites W2035589306 @default.
• W2149357832 cites W2042318626 @default.
• W2149357832 cites W2042557135 @default.
• W2149357832 cites W2069816309 @default.
• W2149357832 cites W2079990645 @default.
• W2149357832 cites W2084201369 @default.
• W2149357832 cites W2092976540 @default.
• W2149357832 cites W2109107385 @default.
• W2149357832 cites W2313827278 @default.
• W2149357832 cites W2338493443 @default.
• W2149357832 cites W3150370576 @default.
• W2149357832 cites W2407772228 @default.
• W2149357832 doi "https://doi.org/10.1093/glycob/cwg034" @default.
• W2149357832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12626384" @default.
• W2149357832 hasPublicationYear "2003" @default.
• W2149357832 type Work @default.
• W2149357832 sameAs 2149357832 @default.
• W2149357832 citedByCount "230" @default.
• W2149357832 countsByYear W21493578322012 @default.
• W2149357832 countsByYear W21493578322013 @default.
• W2149357832 countsByYear W21493578322014 @default.
• W2149357832 countsByYear W21493578322015 @default.
• W2149357832 countsByYear W21493578322016 @default.
• W2149357832 countsByYear W21493578322017 @default.
• W2149357832 countsByYear W21493578322018 @default.
• W2149357832 countsByYear W21493578322019 @default.
• W2149357832 countsByYear W21493578322020 @default.
• W2149357832 countsByYear W21493578322021 @default.
• W2149357832 countsByYear W21493578322022 @default.
• W2149357832 countsByYear W21493578322023 @default.
• W2149357832 crossrefType "journal-article" @default.
• W2149357832 hasAuthorship W2149357832A5043847795 @default.
• W2149357832 hasBestOaLocation W21493578321 @default.
• W2149357832 hasConcept C108625454 @default.
• W2149357832 hasConcept C11960822 @default.
• W2149357832 hasConcept C126322002 @default.
• W2149357832 hasConcept C150903083 @default.
• W2149357832 hasConcept C159654299 @default.
• W2149357832 hasConcept C181199279 @default.
• W2149357832 hasConcept C185592680 @default.
• W2149357832 hasConcept C202751555 @default.
• W2149357832 hasConcept C203014093 @default.
• W2149357832 hasConcept C206212055 @default.
• W2149357832 hasConcept C207001950 @default.
• W2149357832 hasConcept C2775887612 @default.
• W2149357832 hasConcept C2777313579 @default.
• W2149357832 hasConcept C2777404818 @default.
• W2149357832 hasConcept C2777807558 @default.
• W2149357832 hasConcept C2779026604 @default.
• W2149357832 hasConcept C2779134260 @default.
• W2149357832 hasConcept C2779969927 @default.
• W2149357832 hasConcept C2780115458 @default.
• W2149357832 hasConcept C55493867 @default.
• W2149357832 hasConcept C71924100 @default.
• W2149357832 hasConcept C86803240 @default.
• W2149357832 hasConcept C98274493 @default.
• W2149357832 hasConceptScore W2149357832C108625454 @default.
• W2149357832 hasConceptScore W2149357832C11960822 @default.
• W2149357832 hasConceptScore W2149357832C126322002 @default.
• W2149357832 hasConceptScore W2149357832C150903083 @default.
• W2149357832 hasConceptScore W2149357832C159654299 @default.
• W2149357832 hasConceptScore W2149357832C181199279 @default.
• W2149357832 hasConceptScore W2149357832C185592680 @default.
• W2149357832 hasConceptScore W2149357832C202751555 @default.
• W2149357832 hasConceptScore W2149357832C203014093 @default.
• W2149357832 hasConceptScore W2149357832C206212055 @default.
• W2149357832 hasConceptScore W2149357832C207001950 @default.
• W2149357832 hasConceptScore W2149357832C2775887612 @default.
• W2149357832 hasConceptScore W2149357832C2777313579 @default.
• W2149357832 hasConceptScore W2149357832C2777404818 @default.
• W2149357832 hasConceptScore W2149357832C2777807558 @default.
• W2149357832 hasConceptScore W2149357832C2779026604 @default.
• W2149357832 hasConceptScore W2149357832C2779134260 @default.
• W2149357832 hasConceptScore W2149357832C2779969927 @default.
• W2149357832 hasConceptScore W2149357832C2780115458 @default.
• W2149357832 hasConceptScore W2149357832C55493867 @default.
• W2149357832 hasConceptScore W2149357832C71924100 @default.
• W2149357832 hasConceptScore W2149357832C86803240 @default.
• W2149357832 hasConceptScore W2149357832C98274493 @default.
• W2149357832 hasIssue "4" @default.
• W2149357832 hasLocation W21493578321 @default.

• next